The European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio are among those contributing to a €40 million financing to support development of Leyden Laboratories’ antiviral nasal sprays the company said. Since the beginning of 2025, the company has announced a $70 million funding round, a €20 million financing deal with the European Investment Bank, and €30 million in equity financing from the EIC Fund and Invest-NL.
In 2021, Leyden Labs announced that Nanopharm would be develop intranasal formulations of CR9114, and in 2023, the company announced the initiation of a Phase 1 trial of the nasal spray. Earlier this year, Leyden Labs published pre-clinical and clinical data of from studies of its lead candidate, PanFlu (CR9114) intranasal antibody.
Leyden Labs CEO Koenraad Wiedhaup commented, “This financing represents much more than capital. It signals confidence in our scientific approach, our team, and our mission to fundamentally improve how the world protects itself against respiratory viruses. The support from globally respected investors across public health and strategic innovation gives us tremendous momentum as we advance our programs through clinical development and toward global access.”
Read the Leyden Labs press release
